Prognosis of mono- and polydrug resistant pulmonary tuberculosis in the city of Santa Cruz, Bolivia;Pronóstico de la tuberculosis pulmonar mono y polirresistente en la ciudad de Santa Cruz (Bolivia)

Archivos de Bronconeumologia

Volumn 39, Issue 9, 2003, Pages 382-386

  Olle J E ^a,c   Sandy, Goig R ^b  

^a Asoc Catalana Ctrl TB Tercer M   (Spain)

^b Kuratorium Tuberkulose in der Welt   (Bolivia)

^c NONE   (Uganda)

Author keywords

Bolivia; Resistance; Tuberculosis

Indexed keywords

ETHAMBUTOL; ETHAMBUTOL PLUS ISONIAZID; ISONIAZID; PROTIONAMIDE; RIFAMPICIN; STREPTOMYCIN; TUBERCULOSTATIC AGENT;

ADULT; ANTIBIOTIC RESISTANCE; ANTIMICROBIAL THERAPY; ARTICLE; BACTERIUM CULTURE; BOLIVIA; CONTROLLED STUDY; FEMALE; HUMAN; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MULTIDRUG RESISTANCE; POPULATION RESEARCH; PROGNOSIS; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME;

EID: 0041692509     PISSN: 03002896     EISSN: None     Source Type: Journal    
DOI: 10.1157/13050626     Document Type: Article

References (19)

1. Pan American Health Organization. Regional Evaluation Meeting of National Tuberculosis Control Programs. México, 11-14 September, 2000. Washington, DC: PAHO/HCP/HCT176/00.
2. The WHO/IUATLD global project on anti-tuberculosis drug resistance surveillance. Anti-tuberculosis drug resistance in the world. Geneva: WHO/TB/97.229.
3. Ollé-Goig JE, Sandy R. A retrospective study of multidrug-resistant pulmonary tuberculosis in Santa Cruz, Bolivia [remitido].
4. Programa Nacional de Vigilancia y Control de la Tuberculosis. Informe 1996. La Paz, Bolivia: Secretaría Nacional de Salud, 1997.
5. Cullity JE. Cost analysis of Kuratorium Tuberkulose in der Welt in Santa Cruz, Bolivia. London School of Hygiene & Tropical Medicine: Mimeo, 1996.
6. Canetti G, Fox W, Khomenko A. Advances in techniques of testing mycobacterial drug sensitivity and the use of sensitivity tests in tuberculosis control programmes. Bull WHO 1969;41:21-43.
7. The WHO/IUATLD global project on anti-tuberculosis drug resistance surveillance. Anti-tuberculosis drug resistance in the world. Report n.° 2. Prevalence and trends. Geneva: WHO/CDS/TB/2000.278.
8. Sevim T, Ataç G, Güngör G, Törün T, Aksoy E, Gemci I, et al. Treatment outcome of relapse and defaulter pulmonary tuberculosis patients. Int J Tuberc Lung Dis 2002;6:320-5.
9. Grange JM. Drug resistance and tuberculosis elimination. Bull Intern Union Tuberc Lung Dis 1990;65:57-9.
10. Caminero JA. Origen, presente y futuro de las resistencias en tuberculosis. Arch Bronconeumol 2001;37:35-42.
11. Long ER, Ferebee SH. A controlled investigation of streptomycin treatment in pulmonary tuberculosis. Pub Health Rep 1950;65:1421-51.
12. Mitchison DA. How drug resistance emerges as a result of poor compliance during short course chemotherapy for tuberculosis. Int J Tuberc Lung Dis 1998;2:10-5.
13. Sandy R. Evaluación de las resistencias inicial y secundaria a medicamentos anti-tuberculosis en Santa Cruz, Bolivia. 1986-1995. Centro de Diagnóstico Broncopulmonar de la Cruz Roja, Santa Cruz: Mimeo, 1996.
14. Ollé-Goig JE, Cullity JE, Vargas R. A survey of prescribing patterns for tuberculosis treatment among doctors in a Bolivian city. Int J Tuberc Lung Dis 1999;3:74-8.
15. Manalo F, Tan F, Sbarbaro JA, Iseman MD. Community-based short course treatment of pulmonary tuberculosis in a developing nation. Initial report of an eight-month, largely intermittent regimen in a population with a high prevalence of drug resistance. Am Rev Respir Dis 1990;142:1301-5.
16. Singla R, Al-Sharif N, Al-Sayegh MO, Osman MM, Shaikh MA. Influence of anti-tuberculosis drug resistance on the treatment outcome of pulmonary tuberculosis patients receiving DOTS in Riyadh, Saudi Arabia. Int J Tuberc Lung Dis 2002;6:569-72.
17. Mitchison DA, Nunn AJ. Influence of initial drug resistance on the response to short-course chemotherapy of pulmonary tuberculosis. Am Rev Respir Dis 1986;133:423-30.
18. Espinal MA, Kim SJ, Suárez PG, Kam KM, Khomenko AG, Migliori GB, et al. Standard short-course chemotherapy for drug-resistant tuberculosis. Treatment outcomes in 6 countries. JAMA 2000;283:2537-45.
19. Bayer R, Wilkinson D. Directly observed therapy for tuberculosis: history of an idea. Lancet 1995;345:1545-8.